Incyte CORP 8-K filings

Incyte announced robust second quarter 2026 financial results, driven by broad-based sales growth across its portfolio, and raised its full-year financial guidance.

Incyte has finalized its acquisition of Vega Therapeutics, adding the investigational VWD therapy VGA039 to its hematology portfolio.

Incyte Corporation held its Annual Meeting of Shareholders on June 8, 2026, where directors were elected, executive compensation was approved, and the independent auditor was ratified.

Incyte Corporation announced a definitive agreement to acquire Vega Therapeutics, Inc. for $1.25 billion, aiming to expand its hematology portfolio with the investigational antibody VGA039.

Incyte announces robust Q1 2026 financial results with a 20% increase in net sales, driven by key products like Jakafi and Opzelura, alongside significant progress in its late-stage pipeline and anticipated product approvals.

Incyte Corporation announced key executive leadership appointments and title changes to enhance strategic focus and long-term growth plans, effective immediately.

The FDA issued a Complete Response Letter for Incyte's Zynyz sBLA for metastatic NSCLC, citing issues at a third-party manufacturing facility.

Incyte announced robust fourth quarter and full year 2025 financial results, exceeding net product revenue guidance and providing optimistic 2026 forecasts driven by key product growth and pipeline advancements.

Hervé Hoppenot, former Chairman and CEO of Incyte Corporation, has retired from the company's Board of Directors, effective December 10, 2025.

Incyte Corporation announced robust third-quarter 2025 financial results, driven by strong product revenue growth and an upward revision of its full-year net product revenue guidance.

Incyte Corporation announced the appointment of Thomas Tray, its current Chief Accounting Officer, to the additional role of principal financial officer, effective September 16, 2025.

Incyte Corporation announced that Executive Vice President and Chief Financial Officer Christiana Stamoulis will step down effective September 16, 2025.

Incyte Corporation announced robust second-quarter 2025 financial results, driven by significant product revenue growth and key regulatory approvals, leading to increased full-year revenue guidance for Jakafi and other oncology products.

Incyte Corporation announced the retirement of its President and CEO, Hervé Hoppenot, the appointment of William J. Meury as his successor, and an amendment to its 2024 Inducement Stock Incentive Plan to increase authorized shares for new employee equity awards.

Incyte Corporation's stockholders approved significant amendments to its 2010 Stock Incentive Plan and 1997 Employee Stock Purchase Plan, alongside the election of directors and executive compensation, at their Annual Meeting on June 10, 2025.

Incyte Corporation and Novartis Pharma AG have reached a settlement regarding royalty payments for Jakafi, resulting in a $280 million payment and a reduced royalty rate on future sales.

Incyte announces a 20% year-over-year increase in total revenues for Q1 2025, driven by strong performance of Jakafi and Opzelura, and raises its full-year Jakafi revenue guidance.

Incyte announces a 15% increase in total revenues for 2024, driven by Jakafi and Opzelura, and anticipates continued growth with multiple product launches and key milestones in 2025.

Incyte Corporation's Executive Vice President, General Manager, North America, Barry P. Flannelly, has announced his retirement, effective January 6, 2025, with a transition period extending to July 31, 2025.

Incyte announced strong third-quarter 2024 financial results, highlighted by significant revenue growth for Jakafi and Opzelura, and provided updates on key clinical programs.

Incyte's Q2 2024 results show a 9% year-over-year revenue increase, driven by strong sales of Opzelura and Jakafi, alongside a strategic refocus of its R&D pipeline.

Incyte Corporation has amended its revolving credit agreement, extending the maturity date to June 28, 2027.

Incyte Corporation held its annual stockholder meeting on June 12, 2024, where directors were elected, executive compensation was approved, and the appointment of Ernst & Young LLP as the company's independent auditor was ratified.

Incyte Corporation has announced a $2 billion share repurchase program, including a $1.672 billion modified Dutch auction tender offer and a separate agreement with Baker Entities to maintain their ownership stake.

Incyte's first quarter of 2024 saw a 9% year-over-year revenue increase, driven by strong demand for Opzelura and Jakafi, alongside key clinical program advancements and a strategic acquisition.

Incyte announced strong financial results for 2023, driven by Jakafi and Opzelura sales, and provided positive 2024 financial guidance, along with updates on its research and development pipeline.